Form 4: Alkermes Director Cato T. Laurencin Executes Stock Transactions Under 10b5-1 Plan

Director Cato T. Laurencin of Alkermes plc. engaged in multiple stock transactions, including acquisitions and disposals of ordinary shares and derivative securities, under a pre-arranged 10b5-1 trading plan.

Summary

• Cato T. Laurencin, a director at Alkermes plc., executed several transactions involving the company's ordinary shares and derivative securities.
• On December 8, 2024, Laurencin acquired 4,163 ordinary shares through a restricted stock unit award and disposed of 958 shares at $31.46 per share.
• Following these transactions on December 8, Laurencin held 23,013 ordinary shares.
• On December 9, 2024, Laurencin acquired 2,691 ordinary shares through a non-qualified stock option exercise at $22.52 per share and sold 2,691 shares at $31.85 per share.
• After the December 9 transactions, Laurencin held 23,013 ordinary shares.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on February 26, 2023.

Sentiment

Score: 6

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither particularly positive nor negative. The transactions are expected and do not indicate any significant change in the company's outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for insiders to avoid accusations of trading on non-public information.

Risks

• While the transactions are part of a pre-arranged plan, significant sales by insiders could be perceived negatively by the market.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to manage insider transactions.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives and directors of publicly traded companies, such as those at Amgen, Biogen, and Gilead Sciences, to manage their stock transactions and avoid accusations of insider trading.
• The reported transactions are typical for directors who receive stock-based compensation and may periodically sell shares for personal financial management.
• The prices at which the shares were sold are within the range of typical market fluctuations for a company like Alkermes.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on stakeholders as they are part of a pre-arranged trading plan.

Key Dates

Keywords

Alkermes, insider trading, Form 4, stock transactions, Rule 10b5-1, Cato T. Laurencin, stock options, restricted stock units, share disposal, share acquisition